[go: up one dir, main page]

CN112043713B - Application of betulinic acid derivatives in the preparation of medicaments for the treatment of nerve injury diseases - Google Patents

Application of betulinic acid derivatives in the preparation of medicaments for the treatment of nerve injury diseases Download PDF

Info

Publication number
CN112043713B
CN112043713B CN202010960220.4A CN202010960220A CN112043713B CN 112043713 B CN112043713 B CN 112043713B CN 202010960220 A CN202010960220 A CN 202010960220A CN 112043713 B CN112043713 B CN 112043713B
Authority
CN
China
Prior art keywords
betulinic acid
nerve injury
pharmaceutically acceptable
disease
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010960220.4A
Other languages
Chinese (zh)
Other versions
CN112043713A (en
Inventor
陈广通
储呈娇
张永珍
宋开南
宋妍
孙颖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nantong University
Original Assignee
Nantong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantong University filed Critical Nantong University
Priority to CN202010960220.4A priority Critical patent/CN112043713B/en
Publication of CN112043713A publication Critical patent/CN112043713A/en
Application granted granted Critical
Publication of CN112043713B publication Critical patent/CN112043713B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P33/00—Preparation of steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P33/00—Preparation of steroids
    • C12P33/02—Dehydrogenating; Dehydroxylating
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P33/00—Preparation of steroids
    • C12P33/06—Hydroxylating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention belongs to the field of medicines, and discloses an application of betulinic acid derivatives or pharmaceutically acceptable salts thereof in preparing medicines for treating nerve injury diseases. The invention successfully carries out structural modification on the betulinic acid by utilizing a microbial transformation technology to obtain a plurality of novel compounds, and in-vitro nerve cell injury protection tests prove that the compounds have better nerve cell protection activity, can be used as active ingredients of medicaments for treating neurodegenerative diseases, traumatic brain injury and stroke, and have wide application.

Description

Application of betulinic acid derivative in preparing medicine for treating nerve injury diseases
Technical Field
The invention relates to the field of medicines, in particular to application of betulinic acid derivatives in preparing medicines for treating nerve injury diseases.
Background
The incidence of nervous system diseases such as neurodegenerative diseases, traumatic brain injury and stroke rises year by year, and a heavy burden is brought to the society and families. At present, clinical medicines can only relieve part of symptoms, and cannot effectively prevent diseases, improve cognitive states of patients and prevent disease development. The research on the pathogenesis of these common nervous system diseases and the search for active and effective treatment methods have become important tasks in related disciplines such as neuroscience. During the occurrence and development of the above diseases, damage, loss or death of nerve cells in the brain is the most basic pathological change, and the nerve function is often seriously damaged, so that hemiplegia, aphasia, dysnoesia or coma and even death are caused. The importance of preventing cranial nerve injury has attracted the attention of the medical community at home and abroad, and medical scientists are exploring preventive measures from various aspects.
Betulinic acid is a kind of pentacyclic triterpenoid with special structure. The structure is characterized in that the E ring is a five-membered carbon ring, isopropyl at the 19-position of the E ring is substituted by alpha-configuration, and five rings are arranged in a trans-form. The ingredients are mainly distributed in birch bark, spina date seed, radix asparagi, Chinese pulsatilla root and other traditional Chinese medicines and are main effective ingredients of the traditional Chinese medicines. Modern pharmacological research finds that the betulinic acid compound has the effects of resisting bacteria, viruses and tumors, reducing fat, protecting liver and protecting kidney. However, pentacyclic triterpenoid has special structure, lack of active group in the parent nucleus and few reaction sites, and the derivative with hydroxyl, carbonyl and other modifications on the parent nucleus is difficult to obtain by adopting a conventional chemical reaction method. Therefore, the chemical and pharmacological studies of betulinic acid derivatives with parent nucleus structure modification are not complete, and no literature reports about the neuroprotective effect.
Disclosure of Invention
In view of the above, the present invention aims to provide an application of betulinic acid derivatives or pharmaceutically acceptable salts thereof in the preparation of drugs for treating nerve injury diseases, and the betulinic acid derivatives provided by the present invention have good nerve cell repair and protection activity, can be used as active ingredients of drugs for treating neurodegenerative diseases, stroke, brain injury, etc., and have wide applications.
In the invention, the betulinic acid derivative is a compound with a structural formula of formula I-formula VI:
Figure BDA0002680275330000011
the betulinic acid derivative or its pharmaceutically acceptable salt can be used for preparing medicine for treating diseases related to nerve injury.
The betulinic acid derivative or the pharmaceutically acceptable salt thereof provided by the invention can be used for preparing medicines for treating central nerve injury and the like caused by neurodegenerative diseases, trauma or stroke.
In the present invention, the neurodegenerative disease includes alzheimer's disease, parkinson's disease, huntington's disease or amyotrophic lateral sclerosis.
The invention also provides a preparation method of the betulinic acid derivative, which comprises the following steps:
1) fermenting and culturing microorganisms, adding betulinic acid into a culture medium, then performing transformation culture, and removing mycelium to obtain a fermentation broth, wherein the microorganisms are strains of the genus Torulopsis (Circinella); preferably, the strain is Byssochlamus terricola moscae CGMCC 3.2695.
2) Extracting the fermentation liquor, and evaporating the extract to obtain a converted crude extract;
3) and purifying the transformed crude extract by using reverse phase high performance liquid chromatography to obtain a product. Wherein, the preparation conditions of the reversed-phase high performance liquid chromatography are that A semi-preparative chromatographic column YMC ODS-A is 10.0 I.D. times.250 mm, acetonitrile-water (30:70, V/V), the flow rate is 2.5mL/min, and the detection wavelength is 203 nm.
The concentration of betulinic acid in the culture medium in the step 1) of the method is 2-5000 mug/mL.
The extraction solvent in the step 2) of the method is a conventional organic solvent, preferably ethyl acetate.
In the medicine taking the betulinic acid derivative or the pharmaceutically acceptable salt thereof as the active ingredient, one or more pharmaceutically acceptable carriers can be added when needed. The carrier comprises a diluent, an excipient, a filler, an adhesive, a wetting agent, a disintegrating agent, an absorption enhancer, a surfactant, an adsorption carrier, a lubricant and the like which are conventional in the pharmaceutical field, and can be prepared according to a conventional method in the pharmaceutical field.
The invention successfully carries out structural modification on the betulinic acid by utilizing a microbial transformation technology to obtain a new betulinic acid derivative, and the compounds have better nerve cell repairing and protecting activity through in vivo animal experiments and in vitro nerve cell injury protection experiments, can be used as active ingredients of medicaments for treating central nerve injury and the like caused by neurodegenerative diseases, trauma or stroke, and have wide application.
Drawings
FIG. 1 is an HPLC liquid chromatogram of betulinic acid derivatives according to the present invention.
Detailed Description
Example 1 preparation of Compounds of formula I-VI
The compound is prepared by adopting a microbial conversion method and taking betulinic acid as a raw material through the steps of fermentation, extraction, separation and the like. The strain of Torulopsis (Circinella) can be purchased from China academy of sciences microorganism culture Collection management center (CGMCC), and is preserved in a solid slant culture medium at 4 deg.C in a refrigerator.
Taking Circinella muscsae CGMCC 3.2695 as an example, the process for preparing the compound with the structural formula I-VI is as follows:
1) fermentation, transformation and extraction
The Circinella muscae CGMCC 3.2695 was inoculated into 2 250mL triangular flasks (containing 100mL potato medium) as seed solutions. After shaking culture on a shaking table at 160rpm and 26 ℃ for 1 day, 1mL of seed solution was aspirated by a sterile pipette and added to 20 1000mL shake flasks (containing 400mL potato medium) until the hyphae growth was in vigorous phase. After 1 day of shake culture, 20mg betulinic acid (0.2mL, 100mg/mLDMSO solution) was added to each flask, sharing 400mg substrate. Continuing to transform for 7 days under the same conditions, filtering the fermentation broth, filtering to remove mycelium, extracting the filtrate with equal volume of ethyl acetate for 3 times, and concentrating the extractive solution under reduced pressure to dryness to obtain about 0.56g of crude extract of the transformed matter.
2) Purification by reversed phase high performance liquid chromatography
The combined fractions were purified by reverse phase high performance liquid chromatography. The preparation conditions were a semi-preparative column YMC ODS A-5 μm, 10.0X 250mm, acetonitrile-water (30:70, V/V), flow rate 2.5mL/min, and detection wavelength 203 nm. To obtain the compound with the structural formula I-VI6 transformation products, chromatogram shown in FIG. 1, which13The C-NMR data are shown in Table 1.
TABLE 1 carbon spectra data (deuterated pyridines) of Compounds I, II, III, IV, V and VI
Figure BDA0002680275330000021
Figure BDA0002680275330000031
The above results indicate that the obtained compound has the correct structure.
EXAMPLE 2 repair and protective Activity of Compounds I-VI on nerve cells damaged by Hydrogen peroxide
(1) Experimental Material
CO2Incubator (Joean IGO 150); microplate reader (Bio-TEK ELx 800); fluorescence inverted microscope (Olympus IX 51); MTT cell proliferation and cytotoxicity detection kit (Biyuntian Biotech research institute), DMEM high-sugar medium (Gibcol BRL), fetal bovine serum, dimethyl sulfoxide (DMSO), trypsin (Shanghai bioengineering Co., Ltd.), and 30% hydrogen peroxide (H)2O2) (Renjite Chemicals, Technology, Tianjin) and SH-SY5Y cells (tumor research institute, national academy of medical sciences).
(2) Experimental methods
Determination of H for each test Compound pair Using the MTT method2O2Effect of damaged SH-SY5Y cell activity: after digestion with pancreatin, cell counts were performed, and the cell density of the cell suspension was adjusted to 5X 104one/mL, adding 200. mu.L/well of 96-well culture plate, and placing in 5% CO2Constant temperature of 37 ℃ CO2Culturing in an incubator for 12 h. Grouping treatment after cell adherence: control group, model group (H)2O2700. mu. mol/L lesion 4h), model + test compound (1, 10, 20. mu.M) groups. The final volume of each well was 200. mu.L, 3 replicates for each concentration. 24h after drug treatment, 10. mu.L (5mg `) of MTT solution is added to each wellmL, i.e., 0.5% MTT), and incubation continued for 4 h. Measuring the light absorption value of each hole at 490nm of the microplate reader, and calculating the cell survival rate: the cell survival rate is the OD value of the drug-added group/the OD value of the control group.
(3) Results of the experiment
According to the MTT method test result, calculating the betulinic acid derivative I-VI to H2O2The results of the viability of damaged SH-SY5Y cells are shown in Table 2: (###P＜0.001，*P＜0.05，**P＜0.01，***P＜0.001)。
TABLE 2
Figure BDA0002680275330000032
Figure BDA0002680275330000041
Comparison with the control group, H2O2The cell survival rate of the treated group was significantly reduced, indicating successful cell modeling. And H2O2Compared with treatment groups, the donepezil hydrochloride (positive drug) and the betulinic acid derivatives I-VI can both remarkably improve the survival rate of cells, and the betulinic acid derivatives I-VI have remarkable effect of repairing nerve cell injury, show good dose dependence in a certain dose range and can be used as active ingredients of drugs for treating neurodegenerative diseases, stroke and traumatic brain injury.
EXAMPLE 3 Effect of Compound VI of the invention on learning and memory Capacity of aging mouse model
(1) Establishment of aging mouse model
40 SPF male ICR mice with the weight of 22-26 g are randomly divided into 4 groups, namely a control group, a model group and a compound VI group. The mice of the other groups were intraperitoneally injected with D-galactose at a dose of 250mg/kg once a day, except for the administration of the normal saline to the control group, and at the same time, the compound was intragastrically administered at a dose of 10mg/kg to the drug group, and the normal saline was intragastrically administered at an equal volume to the control group and the model group once a day for 6 weeks. Mice developed overt aging characteristics and were used in later experiments.
(2) Experimental methods
The water maze laboratory is an experiment for forcing an experimental animal to swim and searching for a platform hidden in water, the experimental animal needs to memorize the space position and direction to position the platform, and the learning and memory ability of the experimental animal is evaluated by testing the time for finding the platform. The invention uses a circular water pool with the diameter of 1 meter, the water temperature is 20 ℃, and a platform with the diameter of 8cm and 0.9cm lower than the water surface is placed in the water pool. Model mice were trained in the water pool for 4 days prior to the experiment. The head of the mouse is placed in water facing to the wall of the pool, and the position of the mouse randomly takes four directions of east, west, south and north. The time for the animal to find the platform within 60 seconds is recorded, if 60 seconds are exceeded the animal is guided onto the platform and stays for 10 seconds. Each animal was trained 5 times per day, with 30 minute intervals between each training. After the last training, the platform is removed, the experimental animal is placed in the water pool, and the times and time of entering and staying in the quadrant where the platform is originally placed within 120 seconds are recorded. 4 replicates were set for each test group.
(3) Results of the experiment
Compared with the control group, the residence time of the model group mice in the platform quadrant is obviously reduced, and the residence time of the compound VI group is obviously improved, and the results are shown in a figure 1. The result shows that the compound VI can obviously improve the learning and memory ability of mice and can be used as an active ingredient of a medicament for treating neurodegenerative diseases, stroke and traumatic brain injury.
It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are described in the specification and illustrated only to illustrate the principle of the present invention, but that various changes and modifications may be made therein without departing from the spirit and scope of the present invention, which fall within the scope of the invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.

Claims (6)

1.白桦脂酸衍生物或其药学上可成的盐在制备治疗神经损伤疾病的药物中的应用，所述白桦脂酸衍生物选自式Ⅰ～式Ⅵ中的一种：1. The application of a betulinic acid derivative or a pharmaceutically acceptable salt thereof in the preparation of a medicine for the treatment of nerve injury diseases, the betulinic acid derivative is selected from one of formulas I to VI:
Figure FDA0002680275320000011
Figure FDA0002680275320000011
 2.如权利要求1所述的应用，其特征在于，所述神经损伤疾病为神经退行性疾病、创伤引起的中枢神经损伤或中风引起的中枢神经损伤。2 . The use according to claim 1 , wherein the nerve injury disease is neurodegenerative disease, central nerve injury caused by trauma, or central nerve injury caused by stroke. 3 . 3.如权利要求2所述的应用，其特征在于，所述神经退行性疾病包括阿尔兹海默症、帕金森氏症、亨廷顿病或肌萎缩侧索硬化症。3. The use of claim 2, wherein the neurodegenerative disease comprises Alzheimer's disease, Parkinson's disease, Huntington's disease or amyotrophic lateral sclerosis. 4.如权利要求1所述的应用，其特征在于，所述药物含有白桦脂酸衍生物或其药学上可成的盐和药学上可接受的载体，所述白桦脂酸衍生物为式Ⅰ～式Ⅵ中的一种或几种，4. The application according to claim 1, wherein the medicine contains a betulinic acid derivative or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, and the betulinic acid derivative is of formula I ~ one or more of formula VI,
Figure FDA0002680275320000021
Figure FDA0002680275320000021
 5.如权利要求4所述的应用，其特征在于，所述药学上可接受的载体选自稀释剂、赋形剂、填充剂、粘合剂、润湿剂、崩解剂、吸收促进剂、表面活性剂、吸附载体和润滑剂中的一种或多种。5. use as claimed in claim 4 is characterized in that, described pharmaceutically acceptable carrier is selected from diluent, excipient, filler, adhesive, wetting agent, disintegrating agent, absorption enhancer , one or more of surfactants, adsorption carriers and lubricants. 6.如权利要求1～5任一项所述的应用，其特征在于，所述药物为对损伤的神经细胞具有修复和保护作用的药物。6. The use according to any one of claims 1 to 5, wherein the drug is a drug that has repair and protection effects on damaged nerve cells.
CN202010960220.4A 2020-09-14 2020-09-14 Application of betulinic acid derivatives in the preparation of medicaments for the treatment of nerve injury diseases Active CN112043713B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010960220.4A CN112043713B (en) 2020-09-14 2020-09-14 Application of betulinic acid derivatives in the preparation of medicaments for the treatment of nerve injury diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010960220.4A CN112043713B (en) 2020-09-14 2020-09-14 Application of betulinic acid derivatives in the preparation of medicaments for the treatment of nerve injury diseases

Publications (2)

Publication Number Publication Date
CN112043713A CN112043713A (en) 2020-12-08
CN112043713B true CN112043713B (en) 2021-10-12

Family

ID=73611553

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010960220.4A Active CN112043713B (en) 2020-09-14 2020-09-14 Application of betulinic acid derivatives in the preparation of medicaments for the treatment of nerve injury diseases

Country Status (1)

Country Link
CN (1) CN112043713B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113143934B (en) * 2021-04-19 2021-11-30 南通大学 Application of ursolic acid derivative in preparing medicine for preventing or treating cardiovascular diseases
CN113559106A (en) * 2021-09-13 2021-10-29 南通大学 Application of betulonic acid derivative in preparation of medicine for treating nervous system diseases
CN115252624B (en) * 2021-09-13 2023-08-11 南通大学 Betulonic acid derivative and preparation method and application thereof
CN114344313A (en) * 2022-01-28 2022-04-15 河南省科学院高新技术研究中心 Betulinic acid derivatives for preventing or treating neurodegenerative diseases
CN114392262B (en) * 2022-01-28 2024-03-01 威海赛宝工业信息技术研究院有限公司 Betulinic acid derivative for inhibiting nervous system degenerative diseases
CN114848652A (en) * 2022-05-31 2022-08-05 澳门大学 Application of betulinal in preparing medicine for preventing and treating neurodegenerative diseases
CN116077508B (en) * 2022-09-09 2024-12-03 南通大学 Application of oleanane-type triterpene derivative in preparation of cardiovascular disease drugs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1279950A (en) * 1999-03-01 2001-01-17 中国科学院成都生物研究所 Sigma-receptor acting medicine with triterpene compound structure
WO2004037180A2 (en) * 2002-10-21 2004-05-06 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
CN1853637A (en) * 2005-03-11 2006-11-01 中国药科大学 Use of pentacyclic triterpene compound as glycogen phosphorylase inhibitor
CN103342729A (en) * 2013-03-26 2013-10-09 中国科学院上海药物研究所 Caffeoyl substituted pentacyclic triterpenoid derivatives and purpose thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1279950A (en) * 1999-03-01 2001-01-17 中国科学院成都生物研究所 Sigma-receptor acting medicine with triterpene compound structure
WO2004037180A2 (en) * 2002-10-21 2004-05-06 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
CN1853637A (en) * 2005-03-11 2006-11-01 中国药科大学 Use of pentacyclic triterpene compound as glycogen phosphorylase inhibitor
CN103342729A (en) * 2013-03-26 2013-10-09 中国科学院上海药物研究所 Caffeoyl substituted pentacyclic triterpenoid derivatives and purpose thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Betulinic acid protects the neuronal damage in new born rats from isoflurane-induced apoptosis in the developing brain by blocking FASL-FAS signaling pathway;Dongwei Wang等;《Biomedicine & Pharmacotherapy》;20171130;第95卷;第1631-1635页 *

Also Published As

Publication number Publication date
CN112043713A (en) 2020-12-08

Similar Documents

Publication Publication Date Title
CN112043713B (en) Application of betulinic acid derivatives in the preparation of medicaments for the treatment of nerve injury diseases
CN112028964B (en) A kind of betulinic acid derivative and preparation method and application thereof
CN111494390B (en) New application of betulin derivative in preparing medicine for repairing nerve injury
CN109988217B (en) Betulin derivatives and preparation method and application thereof
CN112142819B (en) Application of betulinic acid derivatives in the preparation of antitumor drugs
CN113603744A (en) Betulonic acid derivative and preparation method thereof
CN104592082B (en) Preparation method and application of penicillol D2 derived from Penicillium citrinum
CN113101293B (en) Application of ursolic acid derivative in preparing medicine for treating nervous system diseases
CN109985044B (en) Application of betulin and its derivatives in the preparation of antitumor drugs
CN111904965B (en) Application of betulinic acid derivatives in the preparation of anti-nephropathy drugs
CN108992450B (en) Application of cycloastragenol derivative in preparation of anti-hepatic fibrosis medicine
CN110407792B (en) Secalonic acid J derived from Penicillium oxalate and its preparation method
CN113134006B (en) Application of ursolic acid derivative in preparing antitumor drugs
CN106966887B (en) Compounds isolated from Colletosporum anthracis and preparation method and use thereof
CN109985043B (en) Application of betulin and its derivatives in medicine with anti-hepatic fibrosis effect
CN113712972A (en) Application of betulonic acid derivative in preparation of medicine for treating cardiovascular diseases
CN113559106A (en) Application of betulonic acid derivative in preparation of medicine for treating nervous system diseases
CN112022857B (en) Application of betulinic acid derivative in preparation of anti-liver-lesion medicine
CN113143934B (en) Application of ursolic acid derivative in preparing medicine for preventing or treating cardiovascular diseases
CN109456196B (en) Quinone compound from marine fungi as well as preparation method and application thereof
CN112915091B (en) Application of ursolic acid derivative in preparation of anti-nephropathy medicine
CN113750106A (en) Application of betulonic acid derivative in preparation of antitumor drugs
CN116602971B (en) Application of ursane-type triterpenes in the preparation of drugs for treating nervous system diseases
CN116077508B (en) Application of oleanane-type triterpene derivative in preparation of cardiovascular disease drugs
CN105030790B (en) Application of the Pananxadiol derivatives in prevention or treatment liver disease drug is prepared

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant